Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT
SummaryStrategies for relapse prevention after allogeneic transplantation in acute leukaemia are warranted. A registry ‐based matched‐pair analysis evaluated the efficacy of prophylactic donor lymphocyte infusion (proDLI). Adults receiving proDLI in complete remission (CR) and controls were pair‐matched for age, diagnosis, cytogenetics, stage, donor, gender, conditioning and T‐cell depletion. Eighty‐nine p airs were identified (median follow‐up: 6.9 years). Within the entire cohort, no difference was observed. However, among patients with high‐risk acute myeloid leukaemia (AML) (unfavourable cytogenetics and/or transplanted beyond first CR), proDLI recipients had improved overall survival (69.8% vs. 40.2% in controls,P = 0.027). ProDLI has moderate efficacy, but can contribute to improved outcome in high‐risk AML.
Source: British Journal of Haematology - Category: Hematology Authors: Christoph Schmid,
Myriam Labopin,
Nicolaas Schaap,
Hendrik Veelken,
Michael Schleuning,
Michael Stadler,
Juergen Finke,
Erin Hurst,
Frederic Baron,
Olle Ringden,
Gesine Bug,
Didier Blaise,
Johanna Tischer,
Adrian Bloor,
Jordi Esteve,
Sebast Tags: Short Report Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants | UK Health